CAH
Cardinal Health, Inc.197.89
-2.07-1.04%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q2 '26
Organic core powers growth reaffirmation.
Q&A reinforced broad strength but spotlighted organic core momentum across pharma and other segments, with M&A contributing just 8% of pharma growth and double-digit profit gains in each 'other' business sans ADS. Management detailed mid-teens pharma profit growth implied for H2 despite lapping $10B new customers, while GNPD brand acceleration stemmed from peak service levels and SG&A cuts. No walk-backs; cap alloc stays opportunistic amid leverage flexibility. Core crushes inorganic. GLP-1 and pricing queries drew crisp assurances of muted profit impact. Confident tone persists; investors eye H2 demand durability.
Key Stats
Market Cap
47.02BP/E (TTM)
29.85Basic EPS (TTM)
6.63Dividend Yield
0.01%Recent Filings
8-K
Board Chair retires; successor named
Cardinal Health's Board Chair Gregory B. Kenny retired effective March 20, 2026, after nearly two decades of service steering major transformations. Director Patricia A. Hemingway Hall stepped in immediately, leveraging her decade-plus tenure and prior CEO role at a top health insurer. Smooth transition. Company stays confident in fiscal 2026 outlook ahead of Q3 earnings on April 30.
8-K
CAO Scherer retiring 2027
10-Q
Q2 FY2026 results
Cardinal Health posted Q2 FY2026 revenue of $65.6B, up 19% y/y, driven by branded and specialty pharma sales in its dominant Pharma segment ($60.7B, 93% of total). GAAP operating earnings climbed 29% y/y to $707M while gross margin rate edged up to 3.65% amid MSO and ADS acquisitions; diluted EPS rose 19% y/y to $1.97. Solaris Health closed November 3, 2025 for ~$1.9B cash, recognizing $1.7B goodwill and $278M finite-lived intangibles (2-10 years). Cash fell to $2.8B with $9.0B debt (new 4.5%/5.15% notes), $1.7B operating cash flow, yet full revolver availability under 3.75:1 covenant. Non-GAAP metrics defined and reconciled in 10-Q. Tariffs crimp GMPD margins.
8-K
Q2 revenue +19%, raises guidance
Cardinal Health reported Q2 FY26 revenue up 19% to $65.6 billion, with non-GAAP operating earnings surging 38% to $877 million across all segments. Non-GAAP EPS jumped 36% to $2.63, fueled by brand pharma growth and acquisitions like Solaris Health. It raised FY26 non-GAAP EPS outlook to $10.15-$10.35. Momentum builds.
8-K
Raises FY26 EPS to $10+
Cardinal Health raised its fiscal 2026 non-GAAP diluted EPS outlook to at least $10.00, up from $9.65-$9.85, fueled by strong execution across segments. Specialty revenues now expected to top $50 billion, a 16% three-year CAGR, with smooth navigation of IRA price changes and the new ContinuCare™ Pathway launch partnering with Publix. Momentum builds. Risks include regulatory shifts and integration hurdles.
IPO
Employees
Sector
Industry
BAX
Baxter International Inc.
19.05-0.48
BDX
Becton, Dickinson and Company
196.39-3.70
COR
Cencora, Inc.
341.72-8.60
COSM
Cosmos Health Inc.
0.50+0.09
CVS
CVS Health Corporation
78.29-1.40
HCA
HCA Healthcare, Inc.
469.79-7.19
HSIC
Henry Schein, Inc.
77.05-0.34
MCK
McKesson Corporation
809.96-13.05
OMI
Owens & Minor, Inc.
3.10+0.09
SNYR
Synergy CHC Corp.
1.85-0.11